Adalimumab: A treatment option for pyoderma gangrenosum after failure of systemic standard therapies

Dermatology and Therapy

Volumn 2, Issue 1, 2012, Pages 1-4

  Hinterberger, Louisa ^a   Müller, Cornelia S L ^a   Vogt, Thomas ^a   Pföhler, Claudia ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Adalimumab; Pyoderma gangrenosum; Systemic therapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BETAMETHASONE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXYCODONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE DURATION; DIZZINESS; DRUG DOSE INCREASE; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; NAUSEA; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RECURRENT DISEASE; SKIN ULCER; THERAPY EFFECT; TREATMENT FAILURE;

EID: 84861891820     PISSN: None     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-012-0006-6     Document Type: Article

References (7)

1. Tremezaygues L, Schmaltz R, Vogt T, Reichrath J. Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy (in German). Hautarzt. 2010;61:345-53.
2. Sick I, Trautner B, Ruzicka T. Surgical management of pyoderma gangrenosum (in German). Hautarzt. 2011 Dec 4. (Epub ahead of print).
3. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis. 2009;15:803-6.
4. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13:191-211.
5. Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007;143:306-8.
6. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152:1059-61.
7. Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007;157:1274-5.